Outcome Any outcome Wins (met endpoint / approved) Flops (missed / terminated / rejected) Met endpoint Missed endpoint Terminated / discontinued Mixed results Trial update Approved Rejected (CRL)
Phase Any phase Phase 1 Phase 1/2 Phase 2 (12) Phase 2/3 (1) Phase 3 (13) Phase 4
Condition Any condition Alcohol Use Disorder (AUD) (1) Androgenetic Alopecia (1) Atopic Dermatitis (1) Autism Spectrum Disorder (1) Bipolar 1 Disorder (1) Chronic Spontaneous Urticaria (1) Duchenne Muscular Dystrophy (1) Generalized Anxiety Disorder (2) Hidradenitis Suppurativa (1) Idiopathic Hypersomnia (1) Metastatic Non-Small Cell Lung Cancer (1) Mycobacterium Infections, Nontuberculous (1) Plaque Psoriasis (1) Pneumococcal Disease (1) Polycythemia Vera (1) Post Bariatric Hypoglycemia (1) Pulmonary Hypertension (2) Recurrent IDH1-Mutant High-Grade Glioma (1) Relapsed Diffuse Large B-Cell Lymphoma (1) Relapsing Forms of Multiple Sclerosis (1) Schizophrenia (2) SLE (1) Wet Age-related Macular Degeneration (1)
Company Any company ADC Therapeutics (1) Alkermes plc. (1) Altimmune (1) Alto Neuroscience (1) Alumis (1) Amylyx Pharmaceuticals (1) Apogee Therapeutics (1) ArriVent (1) Avalo Therapeutics (1) Celldex (1) Definium Therapeutics (2) Insmed (1) Kodiak Sciences (1) MapLight (1) MapLight Therapeutics (1) NeOnc Technologies (1) Oruka Therapeutics (1) Rapport Therapeutics (1) REGENXBIO (1) Roivant (1) Silence Therapeutics (1) Tenax Therapeutics (1) TG Therapeutics (1) Vaxcyte (1) Veradermics (1)
Company type All companies Public companies only
Patients Any size Under 100 patients 100–499 patients 500+ patients
Stock move (24h) Any move Big movers (±10%+) Up 10% or more Down 10% or more Any rise Any fall 24h price pending Private / not listed
Announced Any time Today Last 7 days Last 30 days
